- Document Number:
20240000785
- Appl. No:
18/244773
- Application Filed:
September 11, 2023
- نبذة مختصرة :
The invention provides compositions and methods for reducing the volume of menstrual blood loss in a patient, such as a human patient, for instance, that has uterine fibroids, by administration of a gonadotropin-releasing hormone (GnRH) antagonist. Suitable GnRH antagonists useful in conjunction with the compositions and methods described herein include thieno[3,4d]pyrimidine derivatives, such as 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4d]pyrimidine-5-carboxylic acid and the choline salt thereof.
- Claim:
1. A method of reducing the volume of menstrual blood loss in a female human patient, the method comprising administering to the patient a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxpenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in an amount of about 100 mg per day or about 200 mg per day.
- Claim:
2. The method of claim 1, wherein the patient has uterine fibroids.
- Claim:
3. The method of claim 1, wherein the compound is administered to the patient in an amount of about 100 mg per day.
- Claim:
4. The method of claim 1, wherein the compound is administered to the patient in an amount of about 200 mg per day.
- Claim:
5. The method of claim 1, wherein the compound is administered to the patient in the form of a pharmaceutically acceptable salt thereof.
- Claim:
6. The method of claim 5, wherein the pharmaceutically acceptable salt is a choline salt.
- Claim:
7. The method of claim 1, wherein the compound is administered to the patient orally.
- Claim:
8. The method of claim 1, wherein the compound is administered to the patient once daily.
- Claim:
9. A method of treating uterine fibroids in a female human patient in need thereof, the method comprising administering to the patient a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in an amount of about 100 mg per day or about 200 mg per day.
- Claim:
10. The method of claim 9, wherein the compound is administered to the patient in an amount of about 100 mg per day.
- Claim:
11. The method of claim 9, wherein the compound is administered to the patient in an amount of about 200 mg per day.
- Claim:
12. The method of claim 9, wherein the compound is administered to the patient in the form of a pharmaceutically acceptable salt thereof.
- Claim:
13. The method of claim 12, wherein the pharmaceutically acceptable salt is a choline salt.
- Claim:
14. The method of claim 9, wherein the compound is administered to the patient orally.
- Claim:
15. The method of claim 9, wherein the compound is administered to the patient once daily.
- Claim:
16. A kit comprising a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, wherein the compound is present in the kit in a unit dosage form comprising about 100 mg or about 200 mg of the compound, and wherein the kit further comprises a package insert that instructs a user of the kit to perform the method of claim 1.
- Claim:
17. The kit of claim 16, wherein the compound is present in the kit in the form of a pharmaceutically acceptable salt thereof.
- Claim:
18. The kit of claim 17, wherein the pharmaceutically acceptable salt is a choline salt.
- Claim:
19. The kit of claim 16, wherein the compound is present in the kit in a unit dosage form comprising about 100 mg of the compound.
- Claim:
20. The kit of claim 16, wherein the compound is present in the kit in a unit dosage form comprising about 200 mg of the compound.
- Current International Class:
61; 61; 61; 61
- الرقم المعرف:
edspap.20240000785
Processing Request
No Comments.